盤後時段
|
||||
|
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.46/-0.32
|
|
企業價值
147.84M
|
| 資產負債 |
|
每股賬面淨值
0.12
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
455.00K
|
|
每股收益
0.07
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘:2025/11/05 16:28 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy. |

0.8897 

0.89